血清神经元特异性烯醇化酶水平在非霍奇金淋巴瘤中临床意义.docVIP

血清神经元特异性烯醇化酶水平在非霍奇金淋巴瘤中临床意义 　 作者：血清　神经元特异性烯醇化酶　非霍奇金淋巴瘤 【摘要】 　　［目的］探讨血清神经元特异性烯醇化酶(neuronspecific enolase，NSE)水平与非霍奇金淋巴瘤(nonHodgkins lymphoma, NHL)的临床关系。［方法］ 采集40例的NHL患者初诊时和缓解后的全血2ml，离心后分离上层血清，使用化学发光荧光法检测血清NSE浓度。分析NSE与临床分期、有无B症状、年龄等临床指标的关系以及NSE升高组和正常组的生存期。［结果］40例NHL 患者的血清NSE浓度为8.05ng/ml~159.90ng/ml（平均浓度为29.85 ng/ml），62.5%患者血清NSE浓度高于正常值上限（15.2 ng/ml）。11例获得部分或完全缓解的患者治疗前和缓解后的血清NSE平均浓度分别为50.68 ng/ml和9.36 ng/ml，统计分析表明缓解前后血清NSE值差异具有显著性(t=2.491, P=0.032)。Ann Arbor 分期Ⅳ期患者血清NSE比Ⅰ~Ⅲ期的明显增高（Z=2.584, P=0.009）。有B症状患者血清NSE比没有B症状的明显增高（Z=2.417, P=0.015）。血清LDH升高的患者的NSE明显高于血清LDH正常的患者（Z=2.587, P=0.009），且两者之间存在正相关（r= 0.43, P=0.006）。血清NSE正常组1年生存率有高于NSE升高组的趋势（P=0.057）。［结论］ 血清NSE可以作为监测NHL治疗效果和估计预后的一个指标。 　　Clinical Significance of Serum NeuronSpecific Enolase in Patients with nonHodgkins Lymphoma Abstract:［Purpose］ To study the clinical significance of serum Neuronspecific enolase (NSE) in patients with nonHodgkins lymphoma (NHL).［Methods］ The level of serum NSE in 40 NHL patients was assayed by electrochemiluminescence immunoassay method. The relationship between serum NSE with clinical stage, B symptoms, age and survival rate was analyzed. ［Results］ The serum NSE values in 40 patients was in the range from 8.05 ng/ml to 159.90 ng/ml ( mean value of 29.85 ng/ml). Among these patients, the NSE values in 62.5% patients were higher than the cutoff value(15.2 ng/ml). For the eleven patients who achieved remission, the mean serum NSE value at initial diagnosis was 50.68 ng/ml, and the corresponding value after remission was 9.36 ng/ml. Statistical difference was obtained in the NSE value before therapy and after remission (t=2.491, P=0.032). Serum NSE values of the patients with clinical stage Ⅳ were significantly higher than that of the patients with clinical stage Ⅰ~Ⅲ（Z=2.584, P=0.009）. Serum NSE value in the patients with B symptoms significantly higher than that in the patients without B symptoms （Z=2.417,P=0.015）. Serum NSE value in the patients with abnormal LDH levelsignificantly higher